Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mice tested in the elevated plus-maze

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 6, 2002, Pages 1151-1154

  Navarro, José Francisco ^a   Maldonado, Enrique ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

3,4 Methylenedioxymethamphetamine; Anxiety; Elevated plus maze test; Mice

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; MALE; MAZE TEST; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HALLUCINOGENS; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 0036774361     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00250-6     Document Type: Article

References (26)

1. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125:2001;141-149.
2. Bhattacharya S.K., Bhattacharya A., Ghosal S. Anxiogenic activity of methylenedioxymethamphetamine (ecstasy). An experimental study. Biog. Amines. 14:1998;217-237.
3. Cohen R.S., Cocores J. Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). Prog. Neuropsychopharmacol. Biol. Psychiatry. 21:1997;727-734.
4. Gamma A., Frei E., Lehmann D., Pascual-Marqui R.D., Hell D., Vollenweider F.X. Mood state and brain electric activity in ecstasy users. NeuroReport. 11:2000;157-162.
5. Koch S., Galloway M.P. MDMA induced dopamine release in vivo: role of endogenous serotonin. J. Neural Transm. 104:1997;135-146.
6. Liechti M.E., Vollenweider F.X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 16:2001;589-598.
7. Lin H.Q., Burden P.M., Christie M.J., Johnston G.A. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol., Biochem. Behav. 62:1999;403-408.
8. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
9. Maldonado E., Navarro J.F. Effects of 3,4-methylenedyoxymethamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Prog. Neuropsychopharmacol. Biol. Psychiatry. 24:2000;463-472.
10. Maldonado E., Navarro J.F. MDMA ("ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol. Res. 44:2001;27-31.
11. Maldonado E., Navarro J.F., Cárdenas J., Dávila G., Cavas M. Effects of 3,4-methylenedioxymethamphetamine ("ecstasy") on anxiety in the "social interaction test" in male mice. Eur. Neuropsychopharmacol. 10:2000;S341-S342.
12. Manzaneque J.M., Brain P.F., Navarro J.F. Effect of low doses of clozapine on behaviour of isolated and group-housed male mice in the elevated plus-maze test. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;349-355.
13. McCann U.D., Ricaurte G.A. MDMA ("ecstasy") and panic disorder: induction by a single dose. Biol. Psychiatry. 32:1992;950-953.
14. Mechan A.O., Moran P.M., Elliott J.M., Young A.M.J., Joseph M.H., Green A.R. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology. 159:2002;167-175.
15. Morley K.C., McGregor I.S. (±)-3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") increases social interaction in rats. Eur. J. Pharmacol. 408:2000;41-49.
16. Navarro J.F., Maldonado E. Behavioral profile of 3,4-methylenedioxy-methamphetamine (MDMA) in agonistic encounters between male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;327-334.
17. Navarro J.F., Maldonado E. Effects of acute, subchronic and intermittent MDMA ('ecstasy') administration on agonistic interactions between male mice. Aggress. Behav. 28:2002;. in press.
18. Parrot A.C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology. 139:1998;261-268.
19. Parrot A.C., Sisk E., Turner J.D. Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug Alcohol Depend. 60:2000;105-110.
20. Rodgers R.J., Haller J., Holmes A., Halasz J., Walton T., Brain P.F. Corticosterone responses to the plus maze: high correlation with risk assessment in rats and mice. Physiol. Behav. 68:1999;47-53.
21. Soar K., Turner J.J.D., Parrott A.C. Psychiatric disorders in ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum. Psychopharmacol. 16:2001;641-645.
22. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney: a profile of "ecstasy" users and their experiences with the drug. Br. J. Addict. 87:1992;1161-1172.
23. Steele T.D., McCann U., Ricaurte G.A. 3,4-Methylenedioxy-methamphetamine (MDMA, "ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 89:1994;539-551.
24. Stone D.M., Hanson G.R., Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology. 26:1987;1657-1661.
25. Windhaber J., Maierhofer D., Dantendorfer K. Panic disorder induced by large doses of 3,4-methylenedioxymethamphetamine resolved by paroxetine. J. Clin. Psychopharmacol. 18:1998;95-96.
26. Winslow J.T., Insel T.R. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 254:1990;212-220.